Monomerization of Homodimeric Trefoil Factor 3 (TFF3) by an Aminonitrile Compound Inhibits TFF3-Dependent Cancer Cell Survival.
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
09 Sep 2022
09 Sep 2022
Historique:
received:
11
03
2022
entrez:
16
9
2022
pubmed:
17
9
2022
medline:
17
9
2022
Statut:
epublish
Résumé
Trefoil factor 3 (TFF3) is a secreted protein with an established oncogenic function and a highly significant association with clinical progression of various human malignancies. Herein, a novel small molecule that specifically targets TFF3 homodimeric functions was identified. Utilizing the concept of reversible covalent interaction, 2-amino-4-(4-(6-fluoro-5-methylpyridin-3-yl)phenyl)-5-oxo-4H,5H-pyrano[3,2-
Identifiants
pubmed: 36110371
doi: 10.1021/acsptsci.2c00044
pmc: PMC9469493
doi:
Types de publication
Journal Article
Langues
eng
Pagination
761-773Informations de copyright
© 2022 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare the following competing financial interest(s): P.E.L. and T.Z. have previously consulted for Perseis Therapeutics Ltd. P.E.L. is named on PCT application numbers WO 2006/69253 and WO 2008/042435 and US provisional application number 61/059558 and derivatives thereof. V.P., B.B., K.S.R., and P.E.L. are named as inventors on PCT application WO/2018/226155 (PCT/SG2018/050277), Compounds, As Inhibitors of TFF3 Dimerization, Methods and Applications Thereof (and derivatives thereof). P.E.L. is an equity holder in Sinotar Pharmaceuticals Ltd which currently holds the license for this patent.
Références
Breast Cancer Res. 2014 Sep 30;16(5):429
pubmed: 25266665
Signal Transduct Target Ther. 2021 Jul 14;6(1):268
pubmed: 34262017
Cell Death Dis. 2022 Jan 17;13(1):62
pubmed: 35039476
Oncotarget. 2017 Jun 13;8(24):39323-39344
pubmed: 28445151
Medicine (Baltimore). 2015 May;94(20):e860
pubmed: 25997063
PLoS One. 2013 May 15;8(5):e64441
pubmed: 23691218
Regul Pept. 2005 Mar 30;126(3):163-71
pubmed: 15664663
Cancer Lett. 2015 May 28;361(1):104-11
pubmed: 25748388
Endocr Relat Cancer. 2015 Jun;22(3):465-79
pubmed: 25900183
BMC Biophys. 2013 Jun 03;6:7
pubmed: 23731691
Oncogenesis. 2019 Nov 4;8(11):65
pubmed: 31685806
Cell Mol Life Sci. 2005 Dec;62(24):2956-73
pubmed: 16374584
Int J Oncol. 2015 Feb;46(2):563-8
pubmed: 25405728
Neoplasia. 2010 Dec;12(12):1041-53
pubmed: 21170268
Cancers (Basel). 2019 Oct 10;11(10):
pubmed: 31658702
J Clin Oncol. 2009 Mar 1;27(7):1130-6
pubmed: 19124802
Trends Endocrinol Metab. 2017 Aug;28(8):587-596
pubmed: 28622965
Nat Rev Drug Discov. 2017 Feb;16(2):101-114
pubmed: 27885283
Cancer Cell Int. 2017 Jan 5;17:7
pubmed: 28070169
Br J Cancer. 2008 Sep 2;99(5):768-73
pubmed: 18682706
J Cancer Res Ther. 2013 Jul-Sep;9(3):376-80
pubmed: 24125969
Nature. 1995 Oct 26;377(6551):754-7
pubmed: 7477269
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):799-804
pubmed: 10639160
Cell Death Dis. 2022 Mar 25;13(3):265
pubmed: 35332126
Cancer Res. 2016 Jan 15;76(2):453-62
pubmed: 26744521
Br J Clin Pharmacol. 2011 Oct;72(4):647-57
pubmed: 21518389
Int J Oncol. 2005 Feb;26(2):369-77
pubmed: 15645121
Proteins. 2009 Apr;75(1):187-205
pubmed: 18814299
Am J Pathol. 2012 Mar;180(3):904-916
pubmed: 22341453
Cancer Res. 2005 Jan 1;65(1):195-202
pubmed: 15665295
Oncotarget. 2017 Aug 24;8(44):77268-77291
pubmed: 29100386
PLoS Med. 2009 Apr 7;6(4):e1000046
pubmed: 19360088
Invest Ophthalmol Vis Sci. 2016 Jan 1;57(1):56-65
pubmed: 26780310
Oncotarget. 2017 Jun 9;8(43):74188-74208
pubmed: 29088778
PLoS One. 2015 Nov 11;10(11):e0141947
pubmed: 26559818
Nat Chem Biol. 2019 Oct;15(10):937-944
pubmed: 31527835
Prostate. 2004 Nov 1;61(3):209-14
pubmed: 15368472
Nat Chem Biol. 2011 Jan;7(1):22-4
pubmed: 21113170
Nat Commun. 2019 Sep 27;10(1):4408
pubmed: 31562318
PLoS One. 2014 Sep 30;9(9):e107118
pubmed: 25268519
J Pathol. 2002 Aug;197(5):582-8
pubmed: 12210076
Cell Death Dis. 2018 Nov 19;9(12):1147
pubmed: 30451834
Int J Mol Sci. 2017 Jun 15;18(6):
pubmed: 28617312
Cardiovasc Diabetol. 2015 Sep 29;14:129
pubmed: 26415691
Biochim Biophys Acta. 2013 Oct;1834(10):2176-86
pubmed: 23137658
J Biol Chem. 2014 Dec 5;289(49):34296-307
pubmed: 25320076
EBioMedicine. 2019 Apr;42:375-385
pubmed: 30956167
FASEB J. 1995 Apr;9(7):535-40
pubmed: 7737462
J Biol Chem. 1986 Jul 15;261(20):9087-9
pubmed: 3722189
Cell Rep. 2014 Nov 20;9(4):1306-17
pubmed: 25453753
J Clin Invest. 1999 May;103(9):R31-8
pubmed: 10225980
Biochemistry. 2003 Dec 30;42(51):15139-47
pubmed: 14690424
Int J Mol Sci. 2021 May 06;22(9):
pubmed: 34066339
Mol Cell Biol. 2000 Jul;20(13):4680-90
pubmed: 10848594
Biochem Biophys Res Commun. 2000 Aug 11;274(3):576-82
pubmed: 10924320
J Biochem. 2009 Nov;146(5):609-16
pubmed: 19737776
Proc Natl Acad Sci U S A. 2018 Oct 30;115(44):E10505-E10514
pubmed: 30309962
Int J Oncol. 2002 Sep;21(3):655-9
pubmed: 12168114
Int J Mol Sci. 2019 Dec 09;20(24):
pubmed: 31835445
Front Endocrinol (Lausanne). 2018 Feb 13;9:35
pubmed: 29487568